2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Nidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.
Nidia Zapata, MD, associate professor, Instituto Nacional de Cancerologia, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia (AML).
Zapata: The use of triplet combinations is an excellent investigational question that is generating a lot of anticipation, regarding the results that are expected within the space of patients with AML who are not suitable candidates for intensive therapy.
The results [of triplet therapy] have shown significant toxicity, but many of the current approaches focus on adjusting dosing strategies or making changes in the dosing of treatment to make these combinations more tolerable and less toxic for patients. These combinations [are] an excellent [approach], and I believe there is a lot of anticipation for results that will [be read out] at upcoming [medical meetings] to [let us] see these outcomes.
Editor's Note: Dr Zapata's transcript has been translated from Spanish to English.